spacer
The Healthcare Sales & Marketing Network celebrates 27 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  castration-resistant prostate cancer 

 HSMN NewsFeed - 22 Mar 2024
Astellas Receives Positive CHMP Opinion for XTANDI(TM) in Additional Recurrent Early Prostate Cancer Treatment Setting
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 19 Mar 2024
Fusion Pharmaceuticals to be Acquired by AstraZeneca, Accelerating Development of Next-Generation Radioconjugates to Treat Cancer
Biopharmaceuticals Oncology Mergers & Acquisitions
 HSMN NewsFeed - 6 Jul 2022
Immunic, Inc. Strengthens Its Board of Directors with the Appointment of Maria Törnsén
Biopharmaceuticals Personnel
 HSMN NewsFeed - 31 May 2022
Sapience Therapeutics Announces $41 Million Series B Financing to Advance Pipeline of Peptide Therapeutics Targeting Protein-Protein Interactions
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 5 May 2022
Phosplatin Therapeutics Adopts New Corporate Name as Promontory Therapeutics Inc.
Biopharmaceuticals Oncology
 HSMN NewsFeed - 14 Oct 2021
Immunic, Inc. Appoints Patrick Walsh as Chief Business Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 4 May 2021
Astellas' XTANDI(TM) (enzalutamide) Approved by European Commission for Men with Metastatic Hormone-Sensitive Prostate Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 6 Nov 2020
XTANDI(R) (enzalutamide soft capsules) Approved by China NMPA for the Treatment of Non-Metastatic Castration-Resistant Prostate Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 9 Sep 2020
Phosplatin Therapeutics Announces Two Leadership Appointments
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 16 Jun 2020
Cardiff Oncology Secures $13.5 Million Equity Investment from Biotech-Focused Fundamental Institutional Investors Acorn Bioventures and CAM Capital
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 29 May 2020
XTANDI(R) (enzalutamide) Approved by Japan MHLW for the Treatment of Prostate Cancer with Distant Metastasis
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 28 May 2020
Cardiff Oncology Announces Fast Track Designation Granted by the FDA to Onvansertib for Second-Line Treatment of KRAS-Mutated Colorectal Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 14 May 2020
New Oncotype DX(R) Real-world Evidence Shows for the First Time the Practice-changing Impact of TAILORx Results
Diagnostics Oncology
 HSMN NewsFeed - 15 Jul 2019
ESSA Expands Leadership Team by appointing Alessandra Cesano as Chief Medical Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 29 Apr 2019
U.S. FDA Accepts New Drug Application and Grants Priority Review for Darolutamide
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 13 Mar 2019
Hoth Therapeutics Enters into Commercial Licensing Agreement with University of Maryland, Baltimore and Isoprene Pharmaceuticals Inc.
Biopharmaceuticals Dermatology Licensing
 HSMN NewsFeed - 12 Nov 2018
Arix Bioscience plc: Arix Participates in Harpoon $70m Series C Investment Round
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 3 Oct 2018
Trovagene Announces Exclusive License Agreement with MIT for Combination Therapy of Anti-Androgens and Polo-like Kinase Inhibitors in Prostate Cancer
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 29 Aug 2018
Trovagene Announces European Commission Grants Orphan Drug Designation to Onvansertib (PCM-075) for Treatment of Acute Myeloid Leukemia in Europe
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 27 Aug 2018
Cantex Pharmaceuticals, Inc. Receives FDA Fast Track Designation For CX-01 For The Treatment Of Patients Over Age 60 With Newly Diagnosed Acute Myeloid Leukemia (AML)
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 30 Mar 2018
Epic Sciences and Genomic Health Announce Favorable Draft Local Coverage Determination (LCD) on Medicare Coverage for Use of the Oncotype DX(R) AR-V7 Nucleus Detect(TM) Test in Patients with Metastatic Castration-Resistant Prostate Cancer
Diagnostics Oncology Reimbursement
 HSMN NewsFeed - 26 Feb 2018
Genomic Health Expands Offering to Prostate Cancer Patients with Launch of Oncotype DX(R) AR-V7 Nucleus Detect(TM) Test to Predict Treatment Response in Metastatic Disease
Diagnostics Oncology Product Launch
 HSMN NewsFeed - 8 Feb 2018
ZYTIGA(R) (abiraterone acetate) Plus Prednisone Approved for Treatment of Earlier Form of Metastatic Prostate Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 11 Oct 2017
Janssen Submits New Drug Application to U.S. FDA for Apalutamide (ARN-509) to Treat Men with Non-Metastatic Castration-Resistant Prostate Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 20 Sep 2017
Trovagene Strengthens Board of Directors with Appointment of Oncology Development Veteran Dr. Athena Countouriotis
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 14 Sep 2017
Pfizer and Astellas Announce Positive Top-Line Results from Phase 3 PROSPER Trial of XTANDI (enzalutamide) in Patients with Non-Metastatic Castration-Resistant Prostate Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 20 Jul 2017
Churchill Pharmaceuticals Announces NDA Filing Acceptance for YONSA(TM) by the U.S. FDA
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 28 Apr 2017
Epic Sciences Announces Completion of $40 Million Series D Financing
Diagnostics Oncology Venture Capital
 HSMN NewsFeed - 10 Apr 2017
Axovant Sciences Announces Appointment of Dr. David Hung as Chief Executive Officer and Expansion of Board of Directors
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 6 Feb 2017
First U.S. Multi-center Investigational Clinical Trial of 177 Lu PSMA-617 Targeted Radioligand Therapy in Metastatic Castration Resistant Prostate Cancer Receives FDA Clearance
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 3 Jun 2016
Bayer and Orion Expand Clinical Development Program for BAY-1841788 (ODM-201) in Prostate Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 24 Mar 2016
Pivotal Phase III Trial of enzalutamide Initiated in Metastatic Hormone Sensitive Prostate Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 21 Mar 2016
Tokai Strengthens Development Team Through the Addition of Kelly Lindert, M.D., as Executive Vice President and Head of Development
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 20 Oct 2015
Wilson Therapeutics Appoints Andrew Kay as Chairman
Biopharmaceuticals Personnel
 HSMN NewsFeed - 16 Sep 2015
Tokai Pharmaceuticals Augments Commercialization Capabilities through Appointment of Lisa Taylor as Senior Vice President, Commercial Development
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 4 Mar 2015
Bristol-Myers Squibb Signs Exclusive Agreement with Bavarian Nordic for PROSTVAC(R), a Prostate-Specific Antigen-Targeting Cancer Immunotherapy
Biopharmaceuticals Licensing Oncology
 HSMN NewsFeed - 17 Dec 2014
Inovio Pharmaceuticals Appoints Zane Yang, M.D. Vice President, Clinical Development, Oncology
Biopharmaceuticlas Oncology Personnel
 HSMN NewsFeed - 21 Oct 2014
Viamet Announces $60 Million Series D Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 16 Sep 2014
Bayer and Orion Initiate Phase III Trial of ODM-201 in Men with High-Risk Non-Metastatic Castration-Resistant Prostate Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 2 Jun 2014
Orion and Bayer enter global agreement for development and commercialization of novel prostate cancer treatment - Orion upgrades full-year outlook for 2014
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Apr 2014
GTx Announces Departure of CEO
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 3 Apr 2014
Astellas Announces European Regulatory Submission For XTANDI(R) (enzalutamide) Capsules For Chemotherapy-Naive Metastatic Prostate Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 27 Feb 2014
Arno Therapeutics Appoints Lawrence A. Kenyon Chief Financial Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 11 Feb 2014
Tokai Pharmaceuticals Appoints John McBride as Chief Operating Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 24 Jun 2013
XTANDI(TM) (Enzalutamide) Authorized in the European Union for Advanced Prostate Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 5 Jun 2013
Astellas Signs Distribution Agreement With Tecnofarma For Enzalutamide In Latin America
Biopharmaceuticals Distribution
 HSMN NewsFeed - 24 May 2013
Astellas and Medivation Announce Submission of Application for Marketing Approval of Enzalutamide, an Oral Androgen Receptor Inhibitor, in Japan
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 15 May 2013
Tokai Pharmaceuticals Announces $35.5 Million Series E Financing
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 19 Nov 2012
ZYTIGA(R) Receives Positive Regulatory Recommendation in the European Union for Treatment of Metastatic Castration-Resistant Prostate Cancer before Chemotherapy
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 4 Oct 2012
Aragon Pharmaceuticals Raises $50 Million in Series D Financing to Advance Promising Therapeutic Candidates for Hormone-Driven Cancers
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 29 Aug 2012
U.S. FDA Grants Priority Review of ZYTIGA(R) (abiraterone acetate) sNDA for Treatment of Metastatic Castration-Resistant Prostate Cancer Before Chemotherapy
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 9 Aug 2012
Tokai Pharmaceuticals Appoints Adrian M. Senderowicz, M.D., as Chief Medical Officer and Vice President, Medical Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 12 Jun 2012
Tokai Pharmaceuticals’ Galeterone Receives Fast Track Designation from the FDA for the Treatment of Advanced Prostate Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 6 Mar 2012
Aragon Pharmaceuticals Secures $42 Million in Series C Financing to Advance Pipeline of Therapies Targeting Hormone-Driven Cancers
Biopharmaceuticals Oncology Venture Capital Personnel
 HSMN NewsFeed - 25 Oct 2011
Exelixis Appoints Executive Vice President and Chief Commercial Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 23 Aug 2011
FDA Grants Fast Track Designation to Bayer's Investigational Compound Radium-223 Chloride for the Treatment of Castration-Resistant Prostate Cancer That Has Spread to the Bone
Biopharmaceuticals Oncology
 HSMN NewsFeed - 6 Jun 2011
Bayer's Investigational Compound Radium-223 Chloride Met its Primary Endpoint of Significantly Improving Overall Survival in a Phase III Trial in Patients with Castration-Resistant Prostate Cancer That Has Spread to the Bone
Biopharmaceuticals Oncology
 HSMN NewsFeed - 10 Jan 2011
Exelixis’ XL184 Granted Orphan Drug Designation and Assigned the Generic Name Cabozantinib
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 8 Dec 2010
Bavarian Nordic Receives Special Protocol Assessment Agreement From the FDA for Phase 3 Trial of PROSTVAC(R)
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 11 Oct 2010
Abiraterone Acetate Significantly Improved Overall Survival for Patients with Metastatic Advanced Prostate Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 1 Oct 2010
Phase III Data Showing Improved Survival With Jevtana(R) (cabazitaxel) Injection in Second-Line Advanced Prostate Cancer Published in The Lancet
Biopharmaceuticals Oncology
 HSMN NewsFeed - 27 Sep 2010
Pfizer Discontinues Phase 3 Trial of SUTENT(R) in Advanced Castration-Resistant Prostate Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 2 Aug 2010
Aragon Pharmaceuticals Appoints Richard A. Heyman CEO
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 4 Jun 2010
Bayer Presents Clinical Data on Alpharadin in Metastatic Castration-Resistant Prostate Cancer (CRPC)
Biopharmaceuticals Oncology
 HSMN NewsFeed - 29 Apr 2010
Bavarian Nordic Receives FDA Fast Track Designation for PROSTVAC(TM)
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 22 Apr 2010
Aragon Pharmaceuticals Secures $22 Million in Series B Financing
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 30 Mar 2010
Medivation Announces Reduction in Workforce
Biopharmaceuticals Neurology
 HSMN NewsFeed - 17 Dec 2009
Medivation Announces Organizational Changes to Support Anticipated Growth and Future Commercialization
Biopharmaceuticals Personnel
 HSMN NewsFeed - 21 May 2009
Johnson & Johnson Announces Definitive Agreement to Acquire Cougar Biotechnology, Inc.
Biopharmaceuticals Oncology Mergers & Acquisitions
 HSMN NewsFeed - 29 Apr 2009
Cougar Biotechnology Initiates Phase III Trial of CB7630 (Abiraterone Acetate) in Chemotherapy-Nave Castration-Resistant Prostate Cancer Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 18 Mar 2009
Medivation Receives FDA Permission to Initiate Phase 3 Trial of MDV3100 in Castration-Resistant Prostate Cancer
Biopharmaceuticals Oncology
Return to NewsFeed  
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.